ReWalk Robotics Reports Second Quarter 2015 Financial Results YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA

ReWalk Robotics Reports Second Quarter

2015 Financial Results

YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, August 6, 2015 -

ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or "the Company") today announced its financial results for

the three- and six-months ended June 30, 2015.

Highlights of and subsequent to the second quarter include:

"Although second quarter growth was

slower than we expected, demand generation in terms of qualified leads and completed filings for reimbursement grew substantially.

We expanded and modified our training programs to more effectively qualify users and to better assist individuals in advancing

their reimbursement applications," said Larry Jasinski, Chief Executive Officer.

"In July, we launched a significant

new product, the ReWalk Personal 6.0, which offers many superior features over any product in the market or in clinical trials

today. With its streamlined design, including elimination of the backpack, we expect it will increase the number of users and offer

them a better walking experience," he added.

"We remain confident

that the market opportunity and growth potential for ReWalk in our emerging industry is significant. And, that we will continue

to expand our leadership position in wearable exoskeleton market for many years to come," Jasinski concluded.

Second Quarter 2015 Financial

Total revenue was $610,000 for the

second quarter of 2015, up 22% compared with $500,000 in the second quarter of 2014. In the second quarter of 2015, 12 ReWalk systems

were placed compared with 10 ReWalk systems placed in the prior year period.

Gross profit in the second quarter

was $60,000 as compared to a gross loss of $225,000 for the second quarter of 2014 reflecting the positive impact of moving manufacturing

operations to Sanmina in the second half of 2014.

Total operating expenses in the second

quarter of 2015 were $5.9 million, versus $3.6 million in the second quarter of 2014, reflecting ReWalk's increased investment

in sales and market development activities, including the roll-out of ReWalk Personal 6.0, building the reimbursement team and

supporting processes, investing in research and development, and the cost of being a publicly-traded company.

Net loss was $5.8 million for the second

quarter of 2015 versus $4.7 million for the same period last year. Non-GAAP net loss for the second quarter was $5.2 million compared

with non-GAAP net loss of $3.7 million in the prior year quarter.

A reconciliation of net loss to non-GAAP

net loss is included at the end of this press release.

Six Months Ended June 30, 2015

Total revenues were $1.2 million for

the six months ended June 30, 2015, up 32% compared with $945,000 during the six months ended June 30, 2014. In the 2015 six-month

period, 25 ReWalk systems were placed compared to 16 ReWalk systems placed during the same period in 2014.

Gross profit was $93,000 for the six

months ended June 30, 2015 as compared to a gross loss of $423,000 for the six months ended June 30, 2014 reflecting higher volume

of sales in the 2015 period coupled with manufacturing economies of scale and the positive impact of moving manufacturing operations

to Sanmina in the second half of 2014.

Total operating expenses were $11.5

million for the six months ended June 30, 2015 versus $6.4 million in the prior year period, reflecting increase of non-cash share-based

compensation of $0.8 million, increased investment in sales and marketing, and research and development, and the cost of being

a publicly-traded company.

Operating loss for the six months ended

June 30, 2015, was $11.4 million compared with $6.9 million during the prior year period.

Net loss for the six months ended June

30, 2015 was $11.5 million compared with $9.7 million during the six months ended June 30, 2014. Non-GAAP net loss was $10.3

million for the six months ended June 30, 2015, compared with non-GAAP net loss of $6.6 million for the same period last year.

As of June 30, 2015, ReWalk had $31.2

million in cash and cash equivalents.

ReWalk management will host its third

quarter conference call as follows:

A telephone replay will be available

shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode

for the replay is 90065491.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures

and markets wearable robotic exoskeletons for individuals with spinal cord injury. ReWalk's mission is to fundamentally

change the health and life experiences of individuals with spinal cord injury. Founded in 2001, ReWalk has headquarters in the

U.S., Israel and Germany. For more information on the ReWalk systems, please visit http://www.rewalk.com.

Forward Looking Statements

This press release contains forward-looking

information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking

statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s),"

"will," "may," "intends," "anticipate(s)," "look forward," "upcoming,"

"plan," "enables," "potentially," "entitles," and similar expressions are intended

to identify forward-looking statements. These statements include, but are not limited to, statements regarding the underlying sales

for the second quarter of 2015; future availability of reimbursement for ReWalk in Germany and the United States; and the successful

and timely achievement of favorable coverage decisions for ReWalk by additional major insurers. All such statements are subject

to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that

could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information

and statements. These risks and uncertainties include, but are not limited to the following: the market for medical exoskeletons

is new and unproven, and important assumptions about the potential market for ReWalk's products may be inaccurate; the Company

has a limited operating history upon which you can evaluate its business plan and prospects; if ReWalk is unable to expand its

sales, marketing and training infrastructure, it may fail to increase its sales; the health benefits of ReWalk have not been substantiated

by long-term clinical data, which could limit sales; the Company may fail to secure or retain adequate coverage or reimbursement

for ReWalk by third-party payers; the Company depends on a single third-party to manufacture ReWalk and a limited number of third-party

suppliers for certain components of ReWalk; the Company's future growth and operating results will depend on its ability

to develop and commercialize new products and penetrate new markets; the Company operates in a competitive industry that is subject

to rapid technological change, and the Company expects competition to increase; and the Company is subject to extensive governmental

regulations relating to the manufacturing, labeling and marketing of its products. These and other risk factors are set forth

in the Company's final Annual Report on Form 20-F for the year-ended December 31, 2014 filed with the Securities and Exchange

Commission on February 27, 2015, and the Company's other reports filed from time to time with the Securities and Exchange

Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the

date hereof. ReWalk does not undertake any obligation to revise and disseminate forward-looking statements to reflect events

or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

ReWalk is a registered trademark

of ReWalk Robotics Ltd. in Israel.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are

prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ReWalk believes that the use of

non-GAAP accounting measures, including non-GAAP net loss is helpful to its investors. These measures, which the Company refers

to as non-GAAP financial measures, are not prepared in accordance with GAAP.

For the three- and six-months ended June 30, 2015 and 2014,

non-GAAP net loss is calculated as GAAP net loss excluding (i) non-cash share-based compensation expense and (ii) the

revaluation of warrants to purchase convertible preferred shares.

Because of varying available valuation methodologies, subjective